PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us

Our offering

At Evolve, we provide specialised IP strategy services tailored to the unique needs of life sciences companies at every stage of development. Our approach combines scientific expertise with commercial insight to deliver practical intellectual property solutions that drive business value. We understand that effective IP strategy must be both deeply rooted in the science and adapt alongside your company’s growth.

With extensive industry experience and technical knowledge, we are passionate about supporting our clients to realise the full potential of their innovations.

 

Find out more

Evolve IP is able to offer commercially focused, strategic, and clear advice on complex patent portfolios

The team are thoughtful and intuitive and provide a personable service.

Evolve are friendly and knowledgeable and provide practical advice.

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

I recommend Evolve for chemical/pharma patent issues – whether prosecution or complex FTO or loss of exclusivity considerations.

Evolve Intellectual Property offers expertise in patent portfolio management, strategic planning and formalities.

Evolve Intellectual Property is a growing firm, with an excellent reputation.

Evolve is a refreshing change to the traditional patent attorney form approach – much more nimble and responsive.

Fractional in-house

Do you need experienced IP leadership without the overhead of a full-time in-house team?

Our fractional in-house service delivers the senior head of IP expertise you require on a flexible and cost-effective basis, allowing you to scale your IP function precisely when and how you need it. We understand the critical role intellectual property plays in your growth and offer a tailored approach to align your IP strategy directly with your overarching business objectives. Our fractional in-house service seamlessly integrates with your existing team, becoming a trusted partner in managing your day-to-day IP needs. By working with us you will benefit from strategically managed intellectual property helping you to foster innovation, secure investment and gain a competitive edge.

With Evolve you access experienced IP leadership when you need it. Think of us as your dedicated, senior IP resource, readily available to handle the operational complexities while providing expert strategic direction.

Find out more

Sectors

Our team’s combined experience spans traditional pharmaceuticals to cutting-edge advanced therapies, providing you with guidance that is both scientifically informed and commercially pragmatic.

 

Find out more
  • Pharmaceuticals
  • Biotech
  • Biologics
  • Cell & gene therapy
  • AI drug discovery
  • Chemistry

Insights

Visit the blog for our latest commentary on key emerging trends and strategic considerations in pharmaceutical IP.

Read more

Defining the undefinable: The challenges and opportunities for cell therapy IP

  • 13th May 2025
IP strategy for cell therapies presents unique challenges compared to traditional pharmaceuticals and biologics. Previous posts have highlighted the limitations of process patents in cell therapy and the need to think strategically about how best to protect the product from fast-follower competition. This post focusses on an even more fundamental challenge, that of the inherent…

Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide)

  • 9th May 2025
In recent years, Novo Nordisk’s weight loss drug semaglutide, marketed as Wegovy for obesity and Ozempic for diabetes, has become a pharmaceutical phenomenon. As with most successful pharmaceutical products, the remarkable success of semaglutide means we can also expect some high profile IP disputes. In jurisdictions lacking provisions for patent term extension, semaglutide is expected to face generic challenge…

Rose Hughes joins Evolve

  • 7th May 2025
Evolve Intellectual Property is pleased to welcome Dr. Rose Hughes as our new Patent Attorney. Rose joins us with an exceptional background and a wealth of experience gained from her time at AstraZeneca and previously in private practice. Her deep understanding of the pharmaceutical sector is a significant asset to our firm and, most importantly,…

The plausibility of diagnostic inventions: No data, no patent (T 0589/22)

  • 30th April 2025
In T 0589/22, the Board of Appeal revoked a patent for an in vitro diagnostic method on the basis that the claimed diagnostic effect was not rendered plausible. According to the Board of Appeal’s interpretation of the claims, none of the examples in the patent related to the population of subjects defined by the claims.…

OpenAI’s large language model (LLM) patents

  • 29th April 2025
OpenAI’s approach to IP is often cited in the tech industry as an example of a radically new approach to IP. OpenAI has the reputation for protecting its innovations through the use of trade secrets as opposed to patents. However, it appears that this characterisation of OpenAI’s strategy is years out of date.…

AlphaFold: From Nobel Prize to drug-discovery gold mine?

  • 29th April 2025
AlphaFold, a machine learning model for predicting protein structure, is arguably one of the greatest achievements of AI so far. Whilst large language models such as ChatGPT can write poems and make pretty pictures, AlphaFold has the potential to dramatically impact the life-and-death world of drug discovery. AlphaFold represents truly ground-breaking science for which its…

Our team

Evolve is a pharmaceutical specialist IP firm, offering comprehensive intellectual property services built on the experience of our attorneys in both in-house and private practice settings. Evolve is built on the deep expertise of our qualified attorneys in the pharmaceutical and biotech sector. With our personalized approach, scientific backgrounds and industry insights, we deliver tailored and pragmatic IP solutions for our pharmaceutical and biotechnology clients.

Meet the team

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Contact Us